Chelating agents for neurodegenerative diseases

Current Medicinal Chemistry

Volumn 19, Issue 17, 2012, Pages 2760-2772

  Ward, R J ^a,b   Dexter, D T ^b   Crichton, R R ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Faculty of Medicine   (United Kingdom)

Author keywords

Chelation; Copper; Iron; Neurodegeneration; Zinc

Indexed keywords

8 QUINOLINOL; CHELATING AGENT; CLIOQUINOL; COPPER; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DP 109; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; FERRITIN; HLA 20; IRON; NANOPARTICLE; OXIDOPAMINE; PENICILLAMINE; POLYPHENOL; UNCLASSIFIED DRUG; ZINC;

AGING; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CHELATION THERAPY; COPPER DEFICIENCY; DEGENERATIVE DISEASE; DRUG STRUCTURE; HUMAN; IRON BLOOD LEVEL; NEUROPIL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; SENILE PLAQUE; WILSON DISEASE;

EID: 84861899196     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800609689     Document Type: Article

References (66)

1. Perez, L.R., Franz, K.J. Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease Dalton Trans. 2010, 39, 2177-2187
2. Storr, T., Merkel, M., Song-Zhao, GX., Scott, LE., Green, D.E., Bowen, M.L., Thompson, K.H., Patrick, B.O., Schugar, H.J., Orvig, C. Synthesis, characterization, and metal coordinating ability of multifunctional carbohydrate-containing compounds for Alzheimer's therapy. J Am Clin Soc. 2007, 129, 7453-7463
3. Storr, T., Scott, L.E., Bowen, M.L., Green, D.E., Thompson, K.H., Schugar H.J., Orvig C. Glycosylated tetrahydrosalens as multifunctional molecules for Alzheimer therapy. Dalton Trans. 2009, 16, 3034-3043
4. Scott, LE., Page, B.D.G., Patrick, B.O., Orvig, C. Altering pyridinone Nsubstituents to optimize activity as potential prodrugs for Alzheimer's Disease. Dalton Trans. 2008, 7 (45), 6364-6367
5. Schugar, H., Green, DE., Bowen, ML., Scott, LE., Storr, T., Bohmerle, K., Thomas, F., Allen, D.D., Lockman, P.R., Merkel, M., Thompson, K.H., Orvig, C. Angew Chem-Int Edit. 2007, 46, 1716-1718
6. Chen, X., Sievers, E., Hou, Y., Park, R., Tohme, M., Bart, R., Bremner, R., Bading, J.R., Conti, P.S. Integrin alpha v beta 3-targeted imaging of lung cancer Neoplasia. 2005, 7, 271-279
7. Ye, Y., Bloch, S., Xu, B., Achilefu, S. Novel near-infrared fluorescent integrin-targeted DFO analogue. Bioconjugate Chem. 2008, 19, 225-234
8. Hsu, AR., Hou, LC., Veeravagu, A., Greve, JM., Vogel, H., Tse, V., Chen, X. In vivo near-infared fluorescence imaging of integrin alpha v beta 3 in an orthotopic glioblastoma model. Mol Imag Biol. 2006, 8, 315-323
9. Asati, A., Santra, S., Kaittanis, C., Perez, J.M. Surface-charge- dependent cell localization and cytotoxicity of cerium oxide nanoparticles. ACS Nano., 2010, 4, 5321-533
10. Mutla, NB., Degim, Z., Yilmaz, S., Essiz, D., Nacar, A. New perspectives for the treatment of Alzheimer's Disease: Liposomal rivastigmine formulations. Drug Dev Ind Pharm. 2011, 37, 775-789
11. Avramovich-Tirosh, Y., Reznichenko, L., Mit, T., Zheng, H., Fridkin, M., Weinreb, O., Mandel, S., Youdim, M.B. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res. 2007, 4(4),403-11
12. Weinreb, O., Mandel, S., Bar-Am, O., Yogev-Falach, M., Avramovich- Tirosh, Y., Amit, T., Youdim, M.B. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics. 2009, 6(1),163-74
13. Kirkwood, T.B. Systems biology of ageing and longevity Philos Trans R Soc Lond B Biol Sci. 2011, 366(1561),64-70
14. Double, K,L., Dedov, V.N., Fedorow, H., Kettle, E., Halliday, G.M., Garner, B., Brunk, U.T. The comparative biology of neuromelanin and lipofuscin in the human brain. Cell Mol Life Sci. 2008, 65(11),1669-82.
15. Riga, D., Riga, S., Halalau, F., Schneider, F. Brain lipopigment accumulation in normal and pathological aging. Ann N Y Acad Sci. 2006, 1067, 158-63
16. Terman, A., Kurz, T., Navratil, M., Arriaga, E.A., Brunk, U.T. Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondriallysosomal axis theory of aging. Antioxid Redox Signal. 2010, 12(4), 503-35
17. Hohn, A., Jung, T., Grimm, S., Grune, T. Lipofuscin-bound iron is a major intracellular source of oxidants: role in senescent cells. Free Radic Biol Med. 2010, 48, 1100-1108
18. Götz, M,E., Double, K., Gerlach, M., Youdim, M.B., Riederer, P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci. 2004 1012,193-208
19. Crichton, R.R., Ward, R.J. An overview of iron metabolism and cellular criteria for the selections of iron chelators. Curr Med Chem. 2003 10, 997-1004
20. Burdo, J.R., Menzies, S.L., Simpson, I.A., Garrick, L.M., Garrick, M.D., Dolan, K.G., Haile, D.J., Beard, J.L., Connor, J.R. Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J Neurosci Res. 2001, 15;66(6),1198-207
21. Wu, L.J., Leenders, A.G., Cooperman, S., Meyron-Holtz, E., Smith, S., Land, W., Tsai, R.Y., Berger, U.V., Sheng, Z.H, Rouault, T.A. Expression of the iron transporter ferroportin in synaptic vescicles and gthe blood brain barrier. Brain Res. 2004, 1001(1-2), 108-17.
22. Zechel, S., Huber-Wittmer, K., von Bohlen und Halbach, O. Distribution of the iron-regulating protein hepcidin in the murine central nervous system. J Neurosci Res. 2006, 84(4),790-800
23. Zucca, F.A., Bellei, C., Giannelli, S., Terreni, M.R., Gallorini, M., Rizzio, E., Pezzoli, G., Albertini, A., Zecca, L. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J Neural Transm. 2006, 113(6),757-67
24. Halliday, G.M., Ophof, A., Broe, M., Jensen, P.H., Kettle, E., Fedorow, H., Cartwright, M.I., Griffith,s F.M., Shepherd, C.E., Double, K.L. Alphasynuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain. 2005, 128(Pt 11), 2654-64
25. Volles, M.J., Lansbury, P.T. Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry. 2002, 41, 4595-4602
26. Jao, C.,C., Der-Sarkissian, A., Chen, J., Langen, R. Structure of membrane bound alpha-synuclein studied by site directed spin labelling. Proc Natl Acad Sci U S A. 2004, 101(22), 8331-6
27. Payton, J.E., Perrin, R.J., Woods, W.S., George, J.M. Structural determinants of PLD2 inhibition by alpha synuclein. J Mol Biol. 2004, 337(4),1001-9
28. Dexter, D.T., Carayon, A., Vidailhet, M., Ruberg, M., Agid, F., Agid, Y., Lees, A.J., Wells, F.R., Jenner, P., Marsden, C.D. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem. 1990, 55(1),16-20
29. Zecca, L., Zucca, F.A., Wilms, H., Sulzer, D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci. 2003, 26(11), 578-80.
30. Sian, J., Dexter, D.T., Lees, A.J., Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P., Marsden, C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol.1994, 36(3),348-55
31. Crichton, R.R., Dexter, D.T., Ward, R.J. Molecular-based neurodegenerative diseases: from molecular mechanisms to therapeutic strategies. Coord Chem Rev. 2008, 252,1189-1199
32. Faucheux, BA., Martin, ME., Beaumont, C., Hunot, S., Hauw, JJ., Agid, Y., Hirsch, E.C. Lack of upregulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J Neurochem. 2002, 83, 320-330
33. Shachar, D.B., Kahana, N., Kampel, V., Warshawsky, A., Youdim, M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6- hydroxydopamine lesion in rats. Neuropharmacol. 2004, 46, 254-263
34. Hanson, L.R., Roeytenberg, A., Martinez, P.M., Coppes, V.G., Sweet, D.C., Rao, R.J., Marti, D.L., Hoekman, J.D., Matthews, R.B., Frey, W.H.2nd., Panter, S.S. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Therapeut. 2009, 330, 679-686
35. Youdim, M.B., Stephenson, G., Ben Shachar, D. Ironing iron out in Parkinson's disease and other neurodegenerative disease with iron chelators: a lesson from 6-gydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci. 2004, 1012, 306-325
36. Wang, J., Jiang, H., Xie, J.X. Ferroportin 1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur J Neurosci. 2007, 25, 2766-2772
37. Dexter, D., Statton, S., Whitmore, C., Freinbichler, W., Weinberger, P., Tipton, K.T., Della Corte, L., Ward, R.J., Crichton, R.R. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J Neural Transm. 2010, 118, 223-231
38. Perez, C.A., Tong, Y., Guo, M. Iron chelators as potential therapeutic agents for Parkinson's disease. Curr Bioact Comp. 2008, 4, 150-158
39. Son, M., Puttaparthi, K., Kawamata, H., Rajendran, B., Boyer, P.J., Manfredi, G., Elliott, J.L. Overexpression of CCS in G93A-SOD1 mice leads to accelerated neurological deficits with severe mitochondrial pathology. Proc Natl Acad Sci U S A. 2007, 104, 6072-6077
40. Bush, A.I., Tanzi, R.E. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 2008, 5, 421-432
41. Massie, H. R., Aiello, V. R., Iodice, A. A. Changes with age in copper and superoxide dismutase levels in brains of C57BL/6J mice. Mech. Ageing Dev. 1979, 10, 93-99
42. Wang, L.M., Becker, J.S., Wu, Q., Oliveira, M.F., Bozza, F.A., Schwager, A.L., Hoffman, J.M., Morton, K.A. Bioimaging of copper alterations in the aging mouse brain by autoradiography, laser ablation inductively coupled plasma mass spectrometry and immunohistochemistry. Metallomics. 2010, 2(5), 348-53
43. Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G.,Arosio, P., Santambrogio, P., Fariello, R.G., Karatekin, E., Kleinman, M.H., Turro, N., Hornkiewicz, O., Zucca, F.A. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl acad Sce USA. 2004, 101, 9843-9848
44. Strozyk, D., Launer, L.J., Adlard, P.A., Cherny, R.A., Tsatsanis, A., Volitakis, I., Blennow, K., Petrovitch, H., White, L.R., Bush, A.I. Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol Aging. 2009, 30(7), 1069-77
45. Ritchie, C.W., Bush, A.I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R,m Li, Q.X., Tammer, A., Carrington, D., Mavros, C., Volitakis, I., Xilinas, M., Ames, D., Davis, S., Beyreuther, K., Tanzi, R.E., Masters, C.L Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer's disease: a pilot 2 clinical trial. Arch Neurol. 2003, 60, 1685-1691
46. Adlard, P.A., Bush, A.I. Metals and Alzheimer's disease. J Alzheimer's Dis., 2006, 10, 145-163
47. Zatta, P., Drago, D., Bolognin, S., Sensi, L. Alzheimers disease, metal ions and metal homeostatic therapy. Trends in Pharm Sci. 2009, 30, 346-365
48. Deshpande, A., Kawai, H., Metherate, R., Glabe, C.,G., Busciglio, J. A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci. 2009, 29, 4004-4015
49. Lovell, M.A., Smith, J.L., Markesbery, W.R. Elevated zinc transporter-6 in mild cognitive impairment, Alzheimer's disease and Pick disease. J Neuropathol Exp Neurol. 2006, 65, 489-498.
50. Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D. et al Treatment with a copper-zinc chelators markedly and rapidly inhibits ®-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 2001 30, 665-676
51. White, A.R., Reyes, R., Mercer, JF., Camakaris, J., Zheng, H., Bush, A.I., Multhaup, G., Beyreuther, K., Masters, C. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockoput mice Brain Res. 1999, 842, 439-444
52. Hung, Y.H., Bush, A.I., Cherny, R.A. Copper in the brain and Alzheimer's disease. J Biol Inorg Chem. 2010, 15, 61-76
53. Silvestri, L., Camaschella, C. A potential pathogenic role of iron in Alzheimer's disease. J Cell Mol Med. 2008, 12, 1548-1550
54. Crapper McLachlan, D.R., Dalton, A.J., Kruck, T.P., Bell, M.Y., Smith, W.L., Kalow, W., Andrews, D.F. Intramuscular deferrioxamine in patients with Alzheimer's disease. Lancet. 1991, 337, 1304-1308
55. Wu, W.H., Lei, P., Liu, Q., Hu, J., Gunn, A.P., Chen, M.S., Rui, Y.F., Su, X.Y., Xie, Z.P., Zhao, Y.F., Bush, A.I., Li, Y.M. Sequestration of copper from bet-amyloid promotes selective lysis by cylen-hybrid cleavage agents. J Biol Chem. 2008, 283, 1657-1664
56. Gross,i C., Francese, S., Casini, A., Rosi, MC., Luccarini, I., Fiorentini, A., Gabbiani, C., Messori, L., Moneti, G., Casmenti, F. Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2009, 17, 423-440
57. Regland, B., Lehmann, W., Abedini, I., Blennow, K., Jonsson, M., Karlsson, I., Sjogren, M., Wallin, A., Xilinas, M., Gottfries, C.G. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord. 2001, 12, 408-414
58. Adlard, P.A., Cherny, R.A., Finkelstain, D.I., Gautier, E., Robb, E., Cortes, M. et al. (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8 hydroxyl quinoline analogs is associated with decreased interstitial Abeta. Neuron., 2008, 59, 43-55
59. Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C.L., Targum, S., Bush, A.I., Murdoch, R., Wilson, J., Richie, C.W., PBT2-201-EURO study. Safety, efficacy and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase Iia, double blind, randomised placebo-controlled trial. Lancet Neurol. 2008, 7, 779-786
60. Crouch, P.J., Hung, L.W., Adlard, P.A., Cortes, M., Lal, V., Filiz, G., Perez, K.A., Nurjono, M., Caragounis, A., Du, T., Laughton, K., Volitakis, I., Bush, A.I., Li, Q.X., Masters, C.L., Cappai, R., Cherny, R.A., Donnelly, P.S., White, A.R., Barnham, K.J. Increasing Cu bioavailability inhibits Abeta oligomers and tai phosphorylation. Proc Natl Acad Sci. USA 2009, 106, 381-386
61. Lee, J.Y. , Friedman, JE. , Angel, I., Koza, A. , Koh, J.Y. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human bamyloid precursor protein transgenic mice. Neurobiol Aging. 2004, 25, 1315-1321
62. Crichton, R.R., Ward, R.J. Metal-based Neurodegeneration From Molecular Mechanisms to Therapeutic Perspectives, John Wiley and Sons, Chichester, 2006, 1-238.
63. Boddaert, N., Le Quan Sang, K.H., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, JC., Munnich, A., Cabantchik, Z. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110, 401-408
64. Kakhlon, O., Manning, H., Breuer, W., Melamed-Book, N., Lu, C., Cortopassi, G., Munnich, A., Cabantchik, Z.I. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood. 2008, 112, 5219-5227
65. Rogers, J.T., Randall, J.D., Cahill, C.M., Eder, P.S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S.S., Utsuki, T., Greig, N.H., Lahiri, D.K., Tanzi, R.E., Bush, A.I., Giordano, T., Gullans, S.R An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem. 2002, 277(47), 45518-28.
66. Lovell, M.A.; Robertson, J.D.; Teesdale, W.J.; Campbell, J.L.; Markesbery, W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci. 1997, 158, 47-52.